An announcement from Lexaria Bioscience ( (LEXX) ) is now available.
Lexaria Bioscience has completed patient enrollment for its Phase 1b study GLP-1-H24-4, which investigates the safety and efficacy of its DehydraTECH technology in delivering drugs for diabetes control and weight loss. The study, which overenrolled with 24 patients per arm, aims to compare DehydraTECH-processed drugs like semaglutide and tirzepatide against existing formulations, potentially offering improved outcomes and reduced side effects. Results are expected in the fourth quarter of 2025, which could impact Lexaria’s positioning in the drug delivery market.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, specializing in its patented DehydraTECH technology. This technology enhances the bio-absorption and efficacy of oral drug delivery, focusing on improving the way drugs enter the bloodstream and potentially reducing side effects.
YTD Price Performance: -27.39%
Average Trading Volume: 154,959
Technical Sentiment Signal: Strong Buy
Current Market Cap: $28.79M
See more data about LEXX stock on TipRanks’ Stock Analysis page.